Regulatory should have a seat at the C-suite table because regulatory decisions, development pathway, agency engagement timing, evidence strategy; directly shape development timelines, capital efficiency, and what a program can credibly claim at market. When those decisions are made without senior regulatory input, the cost shows up later and compounds across the full program. 

In most emerging biotechs, regulatory strategy is not absent. It is made by default by people who are not regulatory strategists, in rooms where regulatory is not represented. Clinical teams choose endpoints. CMC teams commit to manufacturing approaches. Commercial colleagues set labeling ambitions based on market models. Each of those decisions embeds a regulatory assumption: the endpoint implies a pathway, the manufacturing approach implies a CMC timeline, the labeling ambition implies an evidence bar the program may or may not be designed to clear. 

When there is no senior regulatory voice in the room, those assumptions go untested. They accumulate quietly across functions, each one reasonable in isolation, collectively forming a regulatory position that no one explicitly chose. The problem is not that the individual decisions are wrong. It is that no one with the depth of regulatory experience and the organizational authority to challenge them was present when they were made. 

By the time a regulatory lead is brought in to execute, to prepare the briefing document, to draft the submission sections, to manage the agency interaction, the strategic choices are already locked. The regulatory function inherits a position it did not shape and is expected to defend it. The teams are often capable. The science is often strong. The gap is structural: regulatory thinking arrived after the architecture was set, and the architecture did not leave room for adjustments. 

The cost of reactive regulatory strategy is rarely visible at the point where the decision was made. Regulatory assumptions embedded early in a program; in endpoint selection, CMC planning, development pathway rationale; surface as constraints months or years later, when the options for addressing them are limited by everything that has been built on top of those assumptions. 

A development pathway designed without senior regulatory input shaping the evidence package has compounding impact. The evidence package shapes what the label can credibly claim. What the label can claim shapes the commercial case. What the commercial case looks like shapes investor confidence and, ultimately, valuation. This is the actual sequence in which regulatory misalignment propagates through a program, and each link is harder and more expensive to revisit than the one before. 

The insidious part is where the cost appears. It almost never surfaces at the point where the decision was made. A development choice made in month six shows up as an evidence gap in month twenty-four. An endpoint selection that seemed clinically sound produces data the health authorities consider insufficient for the intended label, and by then the program has spent two years and tens of millions generating data that is not suitable to support approval or acceptance by payors. A CMC decision made to optimize manufacturing speed creates a regulatory bottleneck at submission that may delay filing by two quarters. 

When these problems surface, they look like clinical problems, CMC problems, or commercial problems. Leadership troubleshoots accordingly. What rarely happens is tracing the issue back to its origin: a strategic decision made without regulatory judgment in the room.  

When regulatory has a genuine seat at the leadership table; not just a reporting line, but real influence over development decisions, the program looks different from the start. Nonclinical studies are designed to support clinical dose selection, clinical endpoints are chosen with the label in mind. CMC decisions are made with the regulatory timeline in view. Tradeoffs are surfaced early, when they can still be managed, rather than discovered late, when they can only be absorbed. The evidence narrative is coherent from the beginning, not assembled retrospectively to fit a submission deadline. 

Sophisticated investors doing diligence on Series B and later rounds have learned to read regulatory strategy as a signal of overall management quality. A team with a coherent regulatory path, one that connects the evidence strategy to the labeling ambition to the commercial case, is telling investors something important about how it makes decisions. When an investor asks about the regulatory pathway and the answer is vague, or when the regulatory narrative was clearly assembled after the clinical decisions were already made, that registers as organizational risk. The kind that affects term sheets. 

Regulatory strategy runs through every major decision a company makes: 

• Pathway selection 

• Evidence design 

• Agency engagement 

• Labeling ambition  

Keeping it outside the C-suite is a structural choice with structural consequences. SSI Strategy was built around this problem: bringing senior regulatory leadership into the room where it matters, at the stage where it can still shape the outcome.